#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucopolysaccharidosis III Lymphangiosarcoma Idiopathic inflammatory myopathy Cystic fibrosis Transferrin decreased High-grade B-cell lymphoma White matter lesion Aspergillus infection Inclusion body myositis Biotinidase deficiency Glycogen storage disease type V Staphylococcal infection Liver transplant rejection Thrombotic thrombocytopenic purpura Acute myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Arterial tortuosity syndrome – Treatment Glomerulonephritis membranous Testicular leiomyosarcoma – Trials in Disease Proteus syndrome – Diagnostics Cystic fibrosis lung – Basic Information Prolymphocytic leukaemia Rett syndrome – Diagnostics Carcinoid syndrome – Treatment Hairy cell leukaemia – Treatment Angiosarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tenofovir Disoproxil Fumarate Belzupacap Sarotalocan Naproxen Phleum Pratense Irbesartan Calcipotriol Bilastine Co-Trimoxazole Sar444656 Gadoteric Acid Fluorodopa (18F) Nitrous Oxide Sotorasib Sym024 Azd2693 Sodium Efgartigimod Alfa Technetium (99Mtc) Palmidrol Ifezuntirgene Inilparvovec Tusamitamab Ravtansine More therapies…

    Learn about Your Condition

    Lymphangioleiomyomatosis Eclampsia Epstein-Barr virus infection Aortic disorder Carotid artery occlusion Schizophrenia Meningioma Strongyloidiasis Epicondylitis Hereditary angioedema Rhinitis allergic Myelofibrosis Myopia Kaposi's sarcoma Subarachnoid haemorrhage More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Alectinib
    • Durvalumab
    Belgium France Germany Italy The Netherlands Norway +3

  • Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Vinorelbine
    • Carboplatin
    Austria Czechia France Germany Hungary Italy +3

  • Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Monalizumab
    • Oleclumab
    • Glucose
    France Germany Italy Poland Portugal Spain

  • Long-Term Study for Cancer Patients Using Atezolizumab Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma stage III
    • Renal cancer
    • Non-small cell lung cancer
    Investigated Drugs:
    • Atezolizumab
    Austria Czechia France Hungary Poland Spain

  • Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Crizotinib
    • Entrectinib
    Croatia France Germany Greece Italy The Netherlands +4

  • Study Comparing Dostarlimab and Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Dostarlimab
    France Germany Italy Poland Romania Spain
Previous Page
1 … 32 33 34 35 36 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!